Vertex Pharmaceuticals remains the unshakable leader in cystic fibrosis treatment, with its suite of CF drugs forming the bedrock of its revenue and competitive moat. Yet this foundation is double-edged, exposing the firm to significant risk due to revenue concentration and intense pricing pressures. While its ambitious pipeline spans advanced cell and gene therapies like CASGEVY and neuropathic pain candidates, these programs face steep clinical and commercialization hurdles. Navigating regulatory complexities, reimbursement challenges, and a shifting competitive landscape will be pivotal for Vertex’s growth beyond its traditional core.